COMMUNIQUÉS West-GlobeNewswire

ALK upgrades its full-year revenue and earnings outlook
21/06/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder of the year. [...]
ALK provides update on regulatory process for the house dust mite allergy tablet in China
21/06/2024
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China. ALK will [...]
BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
21/06/2024
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical stage company specializing in serious autoimmune and [...]
BioSenic signe une nouvelle convention de souscription pour un maximum de 2,1 millions d'euros en obligations convertibles
21/06/2024
COMMUNIQUÉ DE PRESSE – INFORMATION PRIVILÉGIÉE Mont-Saint-Guibert, Belgique, le 21 juin 2024, 18h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
21/06/2024
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a [...]
Sharecare enters into definitive agreement to be acquired by Altaris
21/06/2024
Sharecare shareholders to receive $1.43 per share in cash Transaction will deliver significant immediate cash value to stockholders upon closing, best positions Sharecare to continue to deliver exceptional service to [...]
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
21/06/2024
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon, or the Company [...]
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
21/06/2024
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been [...]
Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
21/06/2024
100% of patients enrolled achieved a partial response or better Milder and less frequent drug-related adverse events were observed compared to those associated with Revlimid ® No grade 3 or greater adverse events in [...]
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
21/06/2024
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early [...]
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
21/06/2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a [...]
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
21/06/2024
Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025 Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., June 21, 2024 ( [...]
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27
21/06/2024
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics- [...]
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
21/06/2024
CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental disease CNM-Au8 also demonstrated rescue of mitochondrial deficits in induced astrocytes derived [...]
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
21/06/2024
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the Biennial International [...]
Atlantic International Corp. Acquires Lyneer Staffing Solutions
21/06/2024
Creates National Strategic Staffing, Outsourced Services and Workforce Solutions Company with Over $400 Million in Revenues for the 12 Months Ended December 31, 2023 and Adjusted EBITDA of $5.4 Million ENGLEWOOD CLIFFS [...]
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
21/06/2024
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial • DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen [...]
Trading by management and close relations of management
21/06/2024
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Major shareholder announcement
21/06/2024
June 21, 2024 Company announcement No. 22 Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary [...]

Pages